BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $26,872,000 | +12.9% | 70,402 | -6.0% | 0.02% | +5.0% |
Q4 2020 | $23,796,000 | +34.4% | 74,927 | +4.8% | 0.02% | +5.3% |
Q3 2020 | $17,700,000 | +4.9% | 71,482 | +12.0% | 0.02% | -5.0% |
Q2 2020 | $16,866,000 | +274.2% | 63,810 | -13.1% | 0.02% | +150.0% |
Q1 2020 | $4,507,000 | -69.4% | 73,389 | +9.5% | 0.01% | -52.9% |
Q4 2019 | $14,719,000 | +13.2% | 67,001 | +0.9% | 0.02% | -10.5% |
Q3 2019 | $13,000,000 | -85.7% | 66,427 | +12.6% | 0.02% | -74.3% |
Q2 2019 | $90,894,000 | +840.0% | 59,007 | +21.2% | 0.07% | +428.6% |
Q1 2019 | $9,670,000 | +26.4% | 48,703 | -7.8% | 0.01% | +100.0% |
Q4 2018 | $7,648,000 | -34.8% | 52,842 | -8.1% | 0.01% | -53.3% |
Q3 2018 | $11,736,000 | +3.5% | 57,501 | -25.0% | 0.02% | -6.2% |
Q2 2018 | $11,341,000 | -8.9% | 76,658 | -7.0% | 0.02% | -20.0% |
Q1 2018 | $12,449,000 | +27.5% | 82,421 | +9.3% | 0.02% | +33.3% |
Q4 2017 | $9,766,000 | – | 75,385 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |